New drug targets Hard-to-Treat breast cancer in advanced stage
NCT ID NCT05552001
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants receive the drug intravenously on days 1 and 8 of each 21-day cycle until the disease progresses or side effects become unacceptable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan (also known as Trodelvy), an antibody-drug conjugate given intravenously
- What this could lead to
- If successful, this could provide a more effective treatment option for people with advanced triple-negative breast cancer and help identify which patients are most likely to benefit.
- What could go wrong
- This is a single-arm, open-label trial without a placebo group, so results may be less definitive. The drug can cause side effects like nausea, fatigue, and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New PET tracer could sharpen detection of aggressive breast cancer